CDXC
Signal
Bearish Setup2
Price
1
Move-2.23%Negative session
Volume
1
Volume1.1× avgNormal activity
Technical
1
RSIRSI 44Momentum negative
PRICE
Prev Close
4.93
Open
4.93
Day Range4.75 – 5.00
4.75
5.00
52W Range4.16 – 14.69
4.16
14.69
6% of range
VOLUME & SIZE
Avg Volume
707.0K
FUNDAMENTALS
P/E Ratio
71.5x
Premium valuation
EPS (TTM)
Div Yield
No dividend
Beta
1.73
High vol
Quick Read
TrendInsufficient MA data
Momentum
NEUTRAL
rev -69% · 64% gross margin
Valuation
EXPENSIVE
P/E 72x vs ~20x sector
Health
STRONG
CR 4.9 · FCF $0.17/sh
Lean Bullish
Key MetricsTTM
Market Cap$385.99M
Revenue TTM$30.48M
Net Income TTM$17.38M
Free Cash Flow$42.66M
Gross Margin64.3%
Net Margin13.4%
Operating Margin11.0%
Return on Equity26.1%
Return on Assets16.3%
Debt / Equity0.04
Current Ratio4.86
EPS TTM$0.22

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
5 strong1 concern
73/100
Liquidity
4.86Strong
Leverage
0.04Strong
Coverage
0.0xConcern
ROE
26.1%Strong
ROIC
15.6%Strong
Cash
$65MStrong
ANALYST COVERAGE7 analysts
BUY
Buy
686%
Hold
114%
6 Buy (86%)1 Hold (14%)0 Sell (0%)
Full report →
Stock Health
Composite Score
3 of 4 signals bullish
8/10
Technicals
RSI RangeRSI 44 — Bearish momentum
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 4.86 — healthy liquidity

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings Report · Before OpenMay 7, 2026
Tomorrow
DEx-Dividend DateAug 4, 2026
In 90 days
PDividend PaymentSep 1, 2026
In 118 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

DowntrendGolden Cross · 50D leads 200D by 22.0%

-38.8% vs SMA 50 · -25.3% vs SMA 200

Momentum

RSI44.3
Momentum fading
MACD-0.44
Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$14.69+204.8%
EMA 50
$7.70+59.8%
EMA 200
$6.44+33.6%
Current
$4.82
52W Low
$4.16-13.7%
52-Week RangeNear 52-week low
$4.166th %ile$14.69
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 4 analysts
Analyst revisions:Revenue↑ Revised Up

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2023
$85.6M
$82.3M$88.3M
-$0.02
±5%
Moderate3
FY2024
$97.2M
$96.2M$98.1M
+13.6%$0.04
±50%
Moderate4
FY2025
$118.5M
$117.3M$119.7M
+21.9%$0.13+225.0%
±50%
Moderate3
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryCDXC
Last 8Q
+94.0%avg beat
Beat 4 of 8 quartersMissed 4 Estimates rising
-20%
Q3'23
-69%
Q4'23
+100%
Q1'24
-40%
Q2'24
-100%
Q3'24
+567%
Q4'24
+50%
Q1'25
+265%
Q2'25
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Insider Activity
SEC Filings →
3 Buys/3 SellsNeutral
Lopez Carlos LuisSVP, General C…
$2K
Mar 7
BUY
Jaksch Frank L JrDir
$230K
Dec 13
SELL
Pamir OzanCFO
$21K
Nov 22
BUY
Patrick KristinDir
$82K
Aug 23
SELL
Li Ka Shing10 Percent Own…
$365746.2B
Aug 20
SELL
Chau Hoi Shuen Soli…10 Percent Own…
$365746.2B
Aug 20
BUY
Financials

INSTITUTIONAL OWNERSHIP

1
BSW Wealth Partners
154K
2
Silverberg Bernstein Capital Management LLC
138K
3
Nuveen, LLC
123K
4
PRINCIPAL FINANCIAL GROUP INC
77K
5
Chicago Partners Investment Group LLC
49K
6
State of Alaska, Department of Revenue
29K
7
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC
18K
8
SG Americas Securities, LLC
17K
News & Activity

CDXC News

20 articles · 4h ago

About

chromadex corp. is an integrated, global nutraceutical company devoted to improving the way people age. chromadex scientists partner with leading universities and research institutions worldwide to uncover the full potential of nad and identify and develop novel, science-based ingredients including pteropure® pterostilbene; purenergy®, a caffeine-pteropure® co-crystal; anthorigin™, anthocyanins and niagen® nicotinamide riboside - sold directly to consumers as the supplement, tru niagen®. tru niagen® is helping the world age better®. for more, visit www.chromadex.com like us on facebook here: https://www.facebook.com/chromadex or follow us on twitter @chromadex chromadex® is publicly-traded company (nasdaq:cdxc).

Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Robert Fried
Country
United States
Alex WorshamVice President of Global Marketing & Communications
Andrew ShaoSenior Vice President of Global Regulatory & Scientific Affairs
Carlos LopezSenior Vice President & General Counsel